CervoMed Inc. filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission on November 6, 2026, covering the fiscal quarter ended September 30, 2026.

Key Highlights

  • Shares outstanding: 15,128,540 shares of common stock were outstanding as of November 4, 2026, according to the filing.
  • 2026 Private Placement: The company completed a private placement of 3,360,377 units on June 11, 2026, each unit consisting of one share of common stock (or one pre-funded warrant), one Series B Warrant, and one Series C Warrant.
  • 2026 Registered Direct Offering: The company completed a registered direct offering of 2,500,000 shares of common stock on June 22, 2026.
  • Warrant terms: Series B Warrants cover 3,360,377 shares at $3.32 per share; Series C Warrants cover 3,360,377 shares at $3.14 per share, both issued in connection with the 2026 Private Placement.
  • RewinD-LB Trial: The company disclosed that final results from its Phase 2b clinical trial evaluating neflamapimod for dementia with Lewy bodies were announced in October 2025.
  • Restore Trial: An ongoing Phase 2a clinical trial evaluating neflamapimod for patients recovering from ischemic stroke was initiated in the second quarter of 2025, according to the filing.
  • NIA Grant: The company disclosed a $21.3 million grant from the National Institute on Aging, with $21.0 million awarded in January 2023 and an additional $0.3 million awarded in August 2024.

CervoMed's Q3 2026 Quarterly Disclosure: Financings, Trials, and Capital Structure

CervoMed Inc. (NASDAQ:CRVO), a clinical-stage biopharmaceutical company based in Boston, Massachusetts, filed its Form 10-Q for the quarterly period ended September 30, 2026. The company reported 15,128,540 shares of common stock outstanding as of November 4, 2026. CervoMed is classified as a non-accelerated filer and a smaller reporting company under applicable SEC definitions, according to the filing.

The filing detailed two significant capital raises completed in mid-2026. The 2026 Private Placement, finalized on June 11, 2026, involved 3,360,377 units sold pursuant to a securities purchase agreement dated June 9, 2026. Each unit included either one share of common stock or one pre-funded warrant (exercisable at $0.001 per share), one Series B Warrant at $3.32 per share, and one Series C Warrant at $3.14 per share. Separately, the company completed a registered direct offering of 2,500,000 shares of common stock on June 22, 2026. The company also disclosed that placement agent warrants covering an aggregate of 150,000 shares at $5.00 per share were issued in connection with that registered direct offering.

On the clinical side, the filing noted that final results from the RewinD-LB Trial, a Phase 2b study of neflamapimod in patients with dementia with Lewy bodies, were announced in October 2025. The company's Restore Trial, a Phase 2a study of neflamapimod in patients recovering from ischemic stroke, was described as ongoing, having been initiated in the second quarter of 2025. The filing also referenced the previously disclosed NIA Grant of $21.3 million to support the RewinD-LB Trial. The filing contains forward-looking statements, which the company cautioned "are not guarantees of future performance."

What Was Disclosed

CervoMed filed its Form 10-Q for the quarter ended September 30, 2026, disclosing its capital structure, two mid-2026 equity financings, outstanding warrant terms, the status of its neflamapimod clinical programs, and an NIA grant supporting its dementia with Lewy bodies trial.